Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leadership & People

Set Alert for Leadership & People

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Business Strategies Commercial

Executives On The Move: Sirnaomics, SIGA Technologies and More

Recent executive changes in the industry include C-suite changes at Sirnaomics and Horizon Therapeutics. Meanwhile, new directors were appointed at SIGA Technologies and Forte Biosciences.

Executive Changes Leadership

Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization

Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.

Leadership Business Strategies

Departing Words: Merck’s Ken Frazier Cautions Against Profit Maximization

Pharma CEOs must balance optimizing access and profitability, former Merck CEO and soon-to-be ex executive chairman of the company said. Frazier says health care industry must come to table and admit the “system ain’t working,” talks about the need to protect democracy, in a sweeping interview at the STAT Summit.

Leadership Pricing Debate

How To Turn Around A Struggling Biotech

Leaders from three companies that have managed to achieve successful turnarounds offered some advice and encouragement to biotechs weathering the current financial downturn at the recent Jefferies Healthcare conference in London.

Companies Innovation

Researcher At Heart: Toichi Takenaka's Journey From 'Empty Lab' To CEO

Dr Toichi Takenaka, the first winner of the Lifetime Achievement Award in the inaugural Pharma Intelligence Awards Japan earlier this year, talks to Scrip about his journey from researcher to CEO and today as a mentor for Japanese bioventures. Starting his career in an “empty lab” in the 1960s motivated him to pursue a string of collaborations with universities in Japan and on to the discovery of four successful drugs.

Japan Business Strategies

New Ferring Head Laments Woeful Neglect Of Women's Health

After fighting for years to bridge the gender health gap where many women receive poorer treatment than men from academia and non-profits, Kelle Moley has moved into pharma with Ferring to further her vision.

Clinical Trials Gynecology & Urology

Sosei Heptares Eyes Asia Build-Out On Internal, External Assets

Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.

Asia Pacific Japan

Seagen Taps Epstein As New CEO After A Tumultuous Year

Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.

Leadership Business Strategies

Biogen Lures Viehbacher Back From Venture Capital As CEO

Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.

Leadership Business Strategies

Executives On The Move: Immune-Onc Therapeutics, Lipocine and More

Recent executive moves in the industry include C-suite changes at Lipocine and Actinium Pharmaceuticals. Meanwhile, new directors were appointed at Immune-Onc Therapeutics and Blue Water Vaccines.

Executive Changes Leadership

Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead

Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO Robert Coleman tells Scrip.

Vaccines Leadership
See All
UsernamePublicRestriction

Register